Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of tiragolumab + atezolizumab + bevacizumab in previously untreated PD-L1-positive advanced non-squamous NSCLC
CTR20222490Phase 2Terminated
- Sponsor
- Roche
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab, atezolizumab, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Nov 2022; status: terminated.
02
Drugs
tiragolumabatezolizumabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222490.